STOCK TITAN

Precision Biosciences Inc - DTIL STOCK NEWS

Welcome to our dedicated news page for Precision Biosciences (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Precision Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Precision Biosciences's position in the market.

Rhea-AI Summary
Precision BioSciences regains control of three gene editing programs from Prevail Therapeutics, showcasing ARCUS platform's potential for gene excision and insertion. The collaboration's conclusion allows Precision to independently develop or seek new partners for these programs, maintaining focus on key clinical priorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
iECURE, Inc. receives FDA clearance for ECUR-506 gene editing therapy to treat neonatal onset Ornithine Transcarbamylase deficiency. The therapy will be evaluated in newborn males in the US, UK, and Australia, aiming to provide a mutation-agnostic treatment for liver disorders. The Phase 1/2 trial will assess safety, pharmacokinetics, efficacy, and quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced financial results for 2023, highlighting key achievements such as initiating final IND/CTA enabling studies for PBGENE-HBV, completing licensing agreements with Imugene, TG Therapeutics, and Caribou Biosciences, and completing a $40 million public offering to extend cash runway. The company aims to submit IND and/or CTA for PBGENE-HBV in 2024 and PBGENE-PMM in 2025, advancing gene editing programs and differentiating ARCUS within the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) will release financial results for Q4 and FY 2023 and give a business update on March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences earnings
-
Rhea-AI Summary
Precision BioSciences presents promising data at MMTD conference for PBGENE-PMM program targeting m.3243-associated primary mitochondrial myopathy. ARCUS technology demonstrates efficient elimination of mutant mitochondrial DNA while preserving wild-type DNA, leading to improved mitochondrial function. Precision plans to submit CTA and/or IND for PBGENE-PMM in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) announces CTA approval for ECUR-506 in the UK, a gene editing therapy for OTC deficiency, marking a significant milestone in potentially revolutionizing treatment for infants with OTC deficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
Rhea-AI Summary
iECURE, Inc. announces approval from the U.K. MHRA to expand the OTC-HOPE study for ECUR-506, an investigational gene editing-based therapy for Ornithine Transcarbamylase deficiency. The study aims to assess safety, tolerability, pharmacokinetics, and efficacy of ECUR-506 in newborn males with OTC deficiency, offering a potential alternative to liver transplants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announces a public offering of 2,500,000 shares of common stock and warrants, raising $40.0 million. Leading life sciences investors participate in the financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.24%
Tags
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announces the commencement of a proposed underwritten public offering of its common stock and warrants. The offering includes pre-funded warrants and grants underwriters an option to purchase additional shares. Guggenheim Securities, LLC is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.24%
Tags
Rhea-AI Summary
Precision BioSciences (DTIL) grants Caribou Biosciences a license for gene editing therapy patents. The agreement includes upfront payment, royalties, and milestone payments for commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.28%
Tags
none
Precision Biosciences Inc

Nasdaq:DTIL

DTIL Rankings

DTIL Stock Data

97.66M
5.24M
8.48%
39.81%
4.18%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Durham

About DTIL

precision biosciences, inc. is a biotechnology company located in durham, north carolina, united states.